Cannabidiol: a hope to treat non‑motor symptoms of Parkinson’s Disease Patients
Cannabidiol (CBD) has recently been postulated as an ideal drug to address the treatment of non-motor symptoms of Parkinson’s Disease (PD) due to its multifaceted mechanism of action. The plethora of effects of CBD includes anti-inflammatory, neuroprotective, anxiolytic, and antipsychotic actions, which improve non-motor symptoms of PD and lift the quality of life for patients coping with the illness. Further research is recommended to garner support for FDA approval.
A recently published article serves as a call for research to be conducted to discover how cannabis could impact the management of bipolar disorder (BD). Presented in the article is a full review of the advantages and disadvantages of cannabis-based medicine in the treatment of BD and provides insight into possible mechanisms might affect the pathophysiology of the disorder. The insights listed within the article provide the rationale for examining the endocannabinoid system, specifically the cannabinoid receptor 2, with the hopes of finding therapeutic targets for mood control associated with BD.
Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges
A meta-analysis concerning the role of cannabinoid signaling in immune system regulations revealed current therapeutic benefits, challenges for future research, and exciting new directions. Among the current research, cannabinoids have already been found to suppress inflammation associated with autoimmune diseases, especially in multiple sclerosis, rheumatoid arthritis, Type-1 Diabetes, and Crohn’s Disease. Future cannabis-based therapies aim to improve immune responses to organ donation, bone marrow transplants, and skin grafts. The analysis includes challenges facing future cannabis research such as potential side effects and legal status.
Chronic Stress Is Associated with Pain Precipitation and Elevation in DeltaFosb Expression
Researchers have identified Delta-FosB, an osteosarcoma viral oncogene, as a useful molecular marker of sustained pain. The expression of Delta-FosB is significantly elevated by stress-induced pain, exposing its role in the adaptability of nerves. This study supports theories that Delta-FosB plays an important role in drug addiction, depression, and stress adaptation. The interaction between stress, depression, and pain is something that is not yet well-understood. But, as we learn more about cannabis-based medicine, many of the age-old questions about pain have become much clearer.
Another study with promising results for the use of cannabis to treat chronic pain and fibromyalgia-related symptoms. A large majority of participants reported improved sleep, depression-related symptoms, quality of life and over 20% stopped or reduced the dosage of opioids. https://prn.to/2KXUQUe
Researchers assessed 817 youth (aged 12 to 21) who previously participated in the National Consortium on Alcohol and Neurodevelopment in Adolescence study. They found that 123 subjects (15.2%) had used cannabis in the past year, and that cannabis use impaired inhibitory control, emotional control, and task planning.
Training and Practices of Cannabis Dispensary Staff
How much medical training does your local budtender possess? An online survey sent to medical marijuana dispensary staff reported only 55% of staffers had any formal training for their position, with 20% reporting some background in medical/scientific training. The analysis reported that many among the dispensary staff are recommending cannabis choices that are consistent with current evidence, but some are recommending strains that are either ineffective or exacerbate a patient’s condition. The findings of this study stress the importance of consistent and well-regulated training of dispensary staff.
DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults
Cannabis withdrawal syndrome affects approximately 12.1% of heavy cannabis users and is characterized by symptoms such as nervousness/anxiety, hostility, sleep difficulty, and depressed mood. It has increased prevalence among those suffering from mood disorders, anxiety disorders, and personality disorders. This new data should emphasize the need for physicians to exercise caution when recommending cannabis to individuals who may end up consuming cannabis heavily, and who also suffering from mood, anxiety, or personality disorders